STOP-OHSS Qualitative Study

• Research type

  Research Study

• Full title

  STOP-OHSS - A qualitative study to understand the acceptability and feasibility of new earlier active management of Ovarian Hyper-Stimulation Syndrome (OHSS)

• IRAS ID

  279154

• Contact name

  Mostafa Metwally

• Contact email

  mmetwally@nhs.net

• Sponsor organisation

  Sheffield Teaching Hospital NHS Foundation Trust

• Duration of Study in the UK

  0 years, 11 months, 30 days

• Research summary

  STOP-OHSS - A qualitative study to understand the acceptability and feasibility of new earlier active management of Ovarian Hyper-Stimulation Syndrome (OHSS).

  Ovarian Hyperstimulation Syndrome (OHSS) is a side effect of fertility treatment. The fertility drug (hCG) given to stimulate the ovaries can make them larger, develop cysts and cause fluid to leak into other parts of the body such as the abdomen (this is called ascites).

  OHSS can cause pain, nausea, vomiting, dehydration and changes to blood. This can lead to difficulty breathing, blood clots, problems with the kidneys and liver, and in critical cases even death. Mild forms of OHSS are fairly common (about 1 in every 3 women having fertility treatment). Moderate, severe and critical OHSS are less common, more serious and may need hospital stays. Currently, patients are monitored until the condition becomes severe when they are admitted to hospital for drainage of fluid called paracentesis.

  OHSS can be divided into early or late. Early OHSS occurs within 7 days after the final HCG drug is given. Late OHSS usually happens 10 days or more after the final HCG drug is given. Late OHSS is caused by the natural hCG in the blood from pregnancy. It is usually more severe, lasts longer and is harder to treat. It can have a long-lasting effect on health.

  We will interview 12-16 women who have had OHSS and 12-15 healthcare professionals to find out what they think about our plans to develop new ways to treat OHSS that we want to test in a future trial. We want to know if it is acceptable and possible to:
  1) Treat OHSS earlier than it is treated now
  2) Test a new treatment (GnHR anatagonist injection) for early OHSS
  3) Find out if we can change where and how some treatments are done

• REC name

  East of England - Cambridge South Research Ethics Committee

• REC reference

  20/EE/0123

• Date of REC Opinion

  3 Jul 2020

• REC opinion

  Further Information Favourable Opinion